Wockhardt Limited is a global pharmaceutical and biotechnology organization providing ... research and development activities are carried out.The Company has manufacturing and research facilities in ...

Drug firm Wockhardt on Friday said the national drug regulator has accorded a favourable recommendation for its novel antibiotic developed for the treatment of community-acquired bacterial pneumonia ...

Wockhardt, a Mumbai-based pharmaceutical and biotechnology company, has submitted its phase-3 clinical trial data for Nafithromycin 400 mg, a pneumonia treatment, to the Central Drugs Standard Control ...

Drug firm Wockhardt on Wednesday said it has approached the DCGI for marketing approval of a diabetes treatment medication. The company has filed its fast-acting insulin analog, Aspart injection, with ...

Wockhardt receives a favourable recommendation from CDSCO for its novel antibiotic, Miqnaf, designed for treating community-acquired bacterial pneumonia (CABP) in adults. New Delhi, Oct 11 (PTI) Drug ...

Shares of pharmaceutical and biotech company Wockhardt Ltd gained over 4% on Wednesday, October 16, to touch a 52-week high of ₹1087.95 apiece on the BSE. The sharp movement in the early deals was ...

Mumbai-based Wockhardt Ltd. will launch its novel antibiotic drug WCK 5222, or Zaynich, at discounts of 75-80% in India, the company’s Chairman and Founder, Habil Khorakiwala, said. The drug is ...

The Exchange has sought clarification from Wockhardt Ltd on October 16, 2024, with reference to Movement in Volume.<BR><BR>The reply is awaited.

Wockhardt Ltd., incorporated in the year 1999, is a Mid Cap company (having a market cap of Rs 16,414.05 Crore) operating in Pharmaceuticals sector. Wockhardt Ltd. key Products/Revenue Segments ...